Streamlined European Pathway Needed For Biosimilars To Hit Smaller Targets
Development Costs Are Currently Too High For Smaller-Value Biologics To Be Viable
• By David Wallace
Adrian van den Hoven, Esa Heinonen and Isabell Remus (from center to right) discussed the need for a streamlined European pathway for biosimilars • Source: Medicines for Europe
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
